Research Activity
GSK Partners with Muna Therapeutics to Unlock Novel Alzheimer’s Treatments
Muna Therapeutics, GSK, Alzheimer’s disease, neurodegenerative diseases, spatial transcriptomics, MiND-MAP platform, drug discovery, therapeutic targets.
FDA Approves Imfinzi for Limited-Stage Small Cell Lung Cancer, Marking First Systemic Immunotherapy for LS-SCLC
Imfinzi (durvalumab), Limited-stage small cell lung cancer (LS-SCLC), FDA approval, Systemic immunotherapy, ADRIATIC Phase III trial, Breakthrough Therapy Designation, Priority Review
Nuvig Therapeutics Secures $161M Funding for Phase 2 Study in Autoimmune Diseases
Nuvig Therapeutics, autoimmune diseases, Phase 2 study, funding, NVG-2089, Chronic Idiopathic Demyelinating Polyneuropathy (CIDP), recombinant Fc Ab fragments, synthetic manufacturing.
Kinevant Sciences Discontinues Namilumab Development for Pulmonary Sarcoidosis Following Phase 2 Failure
Namilumab, Pulmonary Sarcoidosis, Phase 2 Study, Kinevant Sciences, RESOLVE-Lung Study, Anti-GM-CSF Monoclonal Antibody
Alligator Bioscience Cuts 70% of Workforce to Address Financial Challenges and Refocus on Pancreatic Cancer Research
Alligator Bioscience, layoffs, cost-cutting, pancreatic cancer research, financial constraints, biotech industry
Pragmatic Clinical Trials: Bridging the Gap Between Research and Real-World Practice
1. Pragmatic Clinical Trials, 2. Real-World Evidence, 3. Clinical Trial Design, 4. Effectiveness Research, 5. Healthcare Decision Making
Merus’s Petosemtamab Demonstrates Promising Efficacy in Expanded HNSCC Dataset
Petosemtamab, HNSCC (Head and Neck Squamous Cell Carcinoma), Merus N.V. (MRUS), Clinical Trial Results, Cancer Treatment, ESMO Asia Congress 2024
Merus’ Petosemtamab Demonstrates Promising Efficacy in Head and Neck Cancer, Enhancing Its ‘Best-in-Disease’ Profile
Petosemtamab, Head and Neck Cancer, Clinical Trials, Merus, ESMO Asia Congress 2024, Biclonics, EGFR and LGR5
Outlook Therapeutics Stock Crashes Following Clinical Trial Failure for Wet AMD Therapy
Outlook Therapeutics, OTLK, stock price, clinical trial failure, wet AMD therapy, ONS-5010, FDA filing
Amgen’s MariTide Shows Promising 20% Weight Loss, Falls Short of Investor Expectations
Amgen, MariTide, weight loss, obesity treatment, clinical trial results